anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The ocular cytokine network plays pivotal roles in terms of the initiation and progression of retinal degeneration. Several types of immunocompetent cells such as microglia participate in inflammation, and a temporal transition in the molecular events of inflammation has been hypothesized. We previously found that the Csf2 gene was induced in the early phase of retinal degeneration. CSF2 participates in the transcriptional activation of several cytokines expressed by microglia; however, whether CSF2 is essential in this context is not known. In this work, we approach this question by using anti-CSF2 neutralizing bntibody and the protein synthesis inhibitor cycloheximide (CHX). We first revealed that CSF2 positively regulated the cytokine induction cascade using a CSF2-neutralizing antibody (anti-CSF2) to treat the microglial cell line that were activated by lipopolysaccharide (LPS). LPS or Lipid A stimulation in the presence of the protein synthesis inhibitor cycloheximide (CHX) led to cytokine superinduction, but suppression of the expression of a few cytokines was also noted in MG5 cells. To examine transitions of the molecular events within LPS-activated microglia, we next performed proteome analysis of MG5 cells stimulated with LPS for 0, 4, and 9 h. The Database for Annotation, Visualization, and Integrated Discovery analysis of differentially expressed proteins showed that various mRNA-modifying molecules were induced after LPS stimulation, in addition to molecules involved in inflammation. However, the numbers of common proteins founded in the comparison between the induced proteins of 4 and 9 h were only one-third and one-half of induced proteins at 4 and 9 h, respectively, suggesting dynamic transition of the induced proteins. LPS-induced mRNA-modifying proteins were almost completely suppressed by CHX, as expected, suggesting that transient induction of transcription-editing proteins plays an important role in terms of the phenotype of inflammation that develops in microglia after LPS stimulation.
PURPOSE: The topic of elective implant removal (IR) in healed fractures of the lower extremity remains controversial, particularly when unspecific symptoms of discomfort, which cannot be quantified, are the primary indication. This study aims to assess indications and outcomes of elective IR of the lower extremity, focusing on unspecific symptoms of discomfort and patient satisfaction postoperatively.
MATERIALS AND METHODS: The retrospective cohort study was conducted at a single level I academic trauma center. We included patients who underwent elective IR for healed fractures of the ankle, foot, patella, and proximal tibia from 2016 to 2021. All patients were followed-up for a minimum of 6 weeks after IR. Our outcomes of interest were patient satisfaction, complications, and alleviation of complaints.
RESULTS: A total of 167 patients were included in the study. Unspecific symptoms of discomfort were the most common reason for IR in all investigated anatomical regions of the lower extremity (47.9%), followed by pain (43.1%) and limited range of motion (4.2%). 4.8% of patients experienced a combination of pain and range of motion limitation. Among all patients, 47.9% reported subjective improvement after IR. IRs based on unspecific symptoms of discomfort were significantly less likely to show alleviation of complaints after IR (27.5%, OR 0.19, p ≤ 0.01). Patients who reported limited range of motion (OR 1.7, p = 0.41) or pain (OR 6.0, p = 0) were significantly more likely to be satisfied after IR. Patients who reported sensitivity to cold weather also showed a decrease of complaints after IR (OR 3.6, p = 0.03). Major complications occurred in 2.1% of cases. The minor complication rate was 8.4% (predominantly impaired wound healing). Smoking patients showed a significantly higher risk of complications after IR (OR 5.2, p = 0.006). Persistent pain postoperatively was detected in 14.7%.
CONCLUSION: When elective IR for consolidated fractures of the lower extremity is primarily motivated by patients' subjective symptoms of discomfort, the risk for postoperative dissatisfaction significantly increases. Objective symptoms on the other hand are associated with higher satisfaction after IR. While the procedure is generally safe, minor complications such as wound healing disorders can occur, especially in smokers. Patient education and well-documented informed consent are critical.
This study will be a prospective, randomized, double blind, crossover interventional design. The crossover allows for equality in number of subjects assigned to each treatment and for subjects to be their own controls. Baseline spirometry will be taken prior to exercise test. Subjects will be prepared for OEP. All exercise will take place on an electromagnetically braked cycle ergometer. Throughout the protocol heart rate, blood pressure, O2 saturation, ventilation, and metabolic data will be recorded. A modified exercise induced asthma protocol will be used. Unlike prior studies, ventilatory kinematics (with isolated diaphragmatic function) will be monitored throughout exercise using biomechanical motion analysis (OEP). This OEP analysis involves compartmentalization of the chest into three sections; 1) pulmonary rib cage, 2) diaphragmatic rib cage, and 3) abdomen to determine the contribution of each component to total lung volume. By measuring the percent contribution of compartment, we are able to better understand its impact on respiration. OEP will be able to quantify and assess the distortion effects of dynamic hyperinflation and obstruction.

Twenty moderate to severe COPD patients will be recruited. Subjects will refrain from their usual inhaled medications for 24 hours prior to the testing session. All subjects will be asked to verify that this is acceptable with their pulmonologist prior to participation. Subjects will also be asked to have their short acting bronchodilators and other regular medications available to be taken if symptoms should occur. During the initial screening, subjects will be familiarized with all procedures. Then baseline pulmonary function testing, and baseline resting OEP measurements will be performed. The subjects will then be randomized to receive either budesonide/formoterol fumarate dihydrate (Symbicort) or a placebo of budesonide only (Entocort EC). At that time, they will receive treatment with either placebo or budesonide/formoterol fumarate dihydrate and after 45 minutes, they will repeat spirometry and OEP and submaximal exercise testing with OEP. After one week, subjects will be tested again and switched to the opposite treatment (i.e. if on budesonide/formoterol fumarate dihydrate initially then switch to placebo and vice versa). The one week washout period between tests will include a resumption of the usual medications. The subjects will refrain from their inhaled medications for 24 hours before the second testing session, but use all of their other usual medications.
Reperfusion therapy is the most effective treatment for acute myocardial infarction. However, reperfusion itself can also cause cardiomyocytes damage. Pyroptosis has been shown to be an important mode of myocardial cell death during ischemia-reperfusion. Non-coding RNAs (ncRNAs) play critical roles in regulating pyroptosis. The regulation of pyroptosis by microRNAs, long ncRNAs, and circular RNAs may represent a new mechanism of myocardial ischemia-reperfusion injury. This review summarizes the currently known regulatory roles of ncRNAs in myocardial ischemia-reperfusion injury and interactions between ncRNAs. Potential therapeutic strategies using ncRNA modulation are also discussed.
PURPOSE:To enable a patient himself/herself to visually confirm the recovery of his/her own chronic disease by attaining the output of a menu suited to the individual chronic disease of an adult patient and furthermore recording the degree of the disease condition. CONSTITUTION:When an operator inputs a disease name, a menu suited to said disease is called out of a disease condition adaptive menu memory means 7. Then the materials and the quantity of the relevant meal are printed via a print means 3 and outputted. Thus the disease condition is inputted. In this case, the disease condition means the important data on the disease, e.g., the blood pressure value, etc., for a hypertensive. A the same time, a history recorded in a patient disease condition history memory means 6 is secured for the data on a 'date' produced at the output of a time counting means 4 as the information showing the input time point. As a result, the contents of a patient disease history memory means 9 are read out as necessary and the recovery process of the disease can be outputted in a visible state.
A lipid-bearing preparation, in particular in the form of a workable paste which is suitable for cosmetic uses, in particular in the region of decorative cosmetics, for coloring and improving the appearance of the skin, lips and eyelids. It is suitable, with suitable additives, also as lip gloss, as fixing means for lipstick, as lip care, as a skin care foundation or as a sun protection agent. That lipid-bearing preparation occurs in water-free form. It is free of waxes, lanolin and lanolin derivatives. It comprises the mixture of at least two oils, namely a straight long-chain ester and liquid polybutene which are put into a pasty form by the addition of hydrogenated triglycerides and finely divided solid substances such as silica, bentonite or hectorite. The preparation may additionally contain coloring agents and suitable cosmetic active substances. Processes for the production of that preparation are also described.
Gastric cancer is a major killer in oncology. The expected overall survival of metastatic patients is less than 2 years. Moreover, most of the patients develop cachexia and worsening of performance over time. As a result, many patients are not fit for second line treatment when eligible. There is currently no approved consensus for third line treatment regimen and in most of the patients it is usually best supportive care.

Irinotecan and docetaxel were tested as single agents or in combination with other drugs (e.g. FOLFIRI) in second line setting. However, the combination of these two drugs together was not tested before. Both agents are active in second line setting which is considered the last chance of the patient in view of lack of evidence in third line setting.
Participation will last approximately 6 months. Participants enrolled in the low-dose intervention arm will receive a weekly produce delivery directly to their home in addition to the completion of 3 questionnaires and collection of the HbA1c at the end of study. The amount of produce provided in this arm will be lower per month per household size than the high dose arm.
A retrospective comparative group will be selected from eligible patients who previously were treated at the University of Pittsburgh Medical Center (UPMC) Diabetes Outpatient Clinics following standard insulin therapy education. Patients in the usual care group will be identified using data available in the electronic medical record system. Propensity score matching will be used to pair intervention and usual care participants during phase 1 of the study (baseline to 3 months).
Control Group subjects will wear the CGM device during their hospitalization, up to 10 days, but glucose readings will NOT be continuously monitored. Control Group subjects will have their glucose management guided by routine standard of care finger sticks. The readings from the CGM device are recorded and reviewed retrospectively, but not used for glucose management during the hospital stay.
Patients receive low-dose, nutritional-grade oral diindolylmethane (DIM) twice daily for 21-28 days in the absence of disease progression or unacceptable toxicity. Treatment may continue for up to 60 days, if surgery is delayed.
Choose both Zusanli(ST36) and Zhongwan（CV12）.Manipulating until achieving a "de Qi" sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days. Received routine antiemetic treatment.
Tramadol: One tablet of 50 mg every 6 hours. The total daily dose will be 200 mg of tramadol.
The invention relates to a premixed feed for preventing Mycoplasma gallisepricum, and a preparation method thereof. The premixed feed comprises, by weight, 5-7 parts of Radix Scutellariae, 4-6 parts of Amur Corktree Bark, 6-10 parts of Rhizoma Dioscoreae Bulbiferae, 6-10 parts of honeysuckle flower, 6-10 parts of Fructus Gardeniae, 4-6 parts of radix bupleuri, 25-35 parts of Folium Isatidis, 6-10 parts of Divaricate Saposhnikovia Root, 4-6 parts of realgar, 4-6 parts of alum, 8-12 parts of licorice root, and 1-3 parts of vitamin C. The premixed feed is composed of above traditional Chinese medicines, and can well prevent and treat the Mycoplasma gallisepricum. The performances of the premixed feed are better than effects of antibiotics on chickens. The performances of Chinese herbal medicines in the above composition make Mycoplasma gallisepticum viruses be outward drained from the chickens through defecation channels. The premixed feed also allows young protomers in the invisible stage of chickens to be killed and then to be drained through the defecation channels in order to eliminate hidden Mycoplasma gallisepricum troubles. The premixed feed adapts to all fertility stages of fryers, and has no residual and no toxic or side effects on the chickens.
Chronic constipation is a prevalent clinical condition. Its etiology and pathogenesis have not yet been fully understood. In recent years, mounting evidence suggests a close association between chronic constipation and intestinal dysbiosis, including alterations in the colony structure and metabolites, as well as the modulation of bowel movements via the brain-gut-microbiota axis. With the deepening of related research, probiotic-related therapies are expected to become a potential first-line treatment for chronic constipation in the future. In this review, we summarize the current research insights into the intricate relationships between chronic constipation and the gut microbiota and briefly discuss several different approaches for treating chronic constipation. The findings from this review may advance our understanding of the pathological mechanisms underlying chronic constipation and, ultimately, translate them into improvements in patient care.
PCT No. PCT/EP95/01892 Sec. 371 Date May 7, 1997 Sec. 102(e) Date May 7, 1997 PCT Filed May 17, 1995 PCT Pub. No. WO95/31967 PCT Pub. Date Nov. 30, 1995The invention relates to an emulsion comprising an aqueous gelled outer phase, a non-aqueous intermediate phase and an inner phase containing an active ingredient incompatible with the gelled outer phase, wherein the outer phase comprises one or more anionic hydrocolloids in an amount of 0.1% to 5% by weight of the weight of the outer phase, the intermediate phase comprises an oil, and the inner phase containing the active ingredient is encapsulated by the intermediate phase. The emulsions are useful for the preparation of antiperspirants, sustained release drug formulations or personal hygiene products.
The invention discloses an externally-applied ointment for treating ringworm of scalp. The externally-applied ointment comprises the following components by weight percent: 8-15% of iodine, 30-40% of honey, 40-45% of pearl powder, 1.05-1.58% of table vinegar and 200-400 U/100g of fungicidin. The preparation method of the ointment comprises the following steps: (1) grinding fungicidin into fine powder for later use; (2) mixing and evenly agitating the fungicidin which is ground into fine powder with honey, nano pearl powder, an iodine solution and the table vinegar, storing at the temperature of 4-10 DEG C for at least three days. The application method of the ointment comprises the following steps: taking the ointment which is stored for three days at the temperature of 4-10 DEG C and evenly coating the ointment on the part with the ringworm of the scalp, wherein the drug delivery range exceeds the diseased region 1-2cm, the ointment is coated twice every day, and seven days are taken as a treatment course. The externally-applied ointment is simple in formula, low in price, convenient to use, good for preparation and treatment operation, and reliable in curative effect, and can be self-made no matter in families, clinics or communities; meanwhile, damage and stimulation to the skin caused by other ointments are eliminated. The external ointment is free of toxic and side effects, and good for popularization in hospitals, communities and families, can be used for a long period of time, and has good social and economic benefits.
BACKGROUND: Our aim was to evaluate the prevalence, mortality, regional and sex distribution of neural tube defects (NTDs) in Finland.
METHODS: Data for this population-based study were collected from 1987 to 2018 from the national health and social welfare registers.
RESULTS: There were in total 1634 cases of NTDs, of which 511 were live births, 72 pregnancies ended in stillbirth and 1051 were terminations of pregnancy due to fetal anomaly (TOPFA). The total prevalence of NTDs was 8.6 per 10 000 births and it increased slightly annually (OR 1.008; 95% CI: 1.002, 1.013) during the 32-year study period. The birth prevalence of NTDs decreased (OR 0.979; 95% CI: 0.970, 0.987), but the prevalence of TOPFA increased annually (OR 1.024; 95% CI 1.017, 1.031). The perinatal mortality of NTD children was 260.7 per 1000 births and the infant mortality was 184.0 per 1000 live births, whereas these measures in the general population were 4.6 per 1000 births and 3.3 per 1000 live births, respectively. There was no difference in the NTD prevalence between males and females (P-value 0.77). The total prevalence of NTDs varied from 7.1 to 9.4 per 10 000 births in Finland by region.
CONCLUSIONS: Although the majority of NTDs are preventable with an adequate folic acid supplementation, the total prevalence increased in Finland during the study period when folic acid supplementation was mainly recommended to high-risk families and to women with folic acid deficiency. NTDs remain an important cause of infant morbidity and mortality in Finland.
PROBLEM TO BE SOLVED: To provide a secure and easy method of manufacturing an adhesive tape shaped like grille by cutting a lengthy primary roll of tape into plural strips and sticking a certain number of the cut strips of tape to release paper to form a new primary roll of strips of tape, then cutting another primary roll along its lengthwise direction taking a certain space and sticking them to the new primary roll so as to form a grille like pattern. SOLUTION: A lengthy primary roll 19 of tape, which as a release paper 17, is cut into plural strips 4 and 5 by a cutter knife 44. Peeling off release paper 17 of these every other strips and sticking them to release paper 3 to form a primary roll 16 of vertically stripped tape. The strips 5 are made to be a primary tape roll 27 with horizontal strips, which is cut at a certain space a little bit narrower than the release paper 3. The end part 5a of this strip 5 is folded by a folding part 35 and the end part 5a is stuck to one side of the vertical tape 4 of the primary roll 16. Then, the strip 5 is stuck to the primary roll 16 as it is being peeled off from the primary roll 27 by shifting the folding part 35.
Hydroxypropyl-β-cyclodextrin (HP-β-CD) is the solubilizing excipient used in itraconazole oral solution. 

Hydroxypropyl-β-cyclodextrin (HP-β-CD) was found to produce neoplasms in the large intestine at 5,000 mg/kg/day in rat carcinogenicity study. This dose was about 3 times amount contained in the recommended clinical dose of itraconazole oral solution (16 g) based on body surface area comparisons. The clinical relevance of this finding is unknown. The slightly higher incidence of adenocarcinomas in the large intestines was linked to the hypertrophic/hyperplastic and inflammatory changes in the colonic mucosa brought about by HP-β-CD-induced increased osmotic forces. 

In addition, HP-β-CD was found to produce pancreatic exocrine hyperplasia and neoplasia when administered orally to rats at doses of 500, 2,000 or 5,000 mg/kg/day for 25 months. Adenocarcinomas of the exocrine pancreas produced in the treated animals were not seen in the untreated group and are not reported in the historical controls. The maximum recommended clinical dose of itraconazole oral solution contains approximately 3.3 times the amount of HP-β-CD as was in the 500 mg/kg/day dose, based on body surface area comparisons. This finding was not observed in the mouse carcinogenicity study at doses of 500, 2,000 or 5,000 mg/kg/day for 22 to 23 months. This finding was also not observed in a 12-month toxicity study in dogs or in a 2-year toxicity study in female cynomolgus monkeys. 

Since the development of the pancreatic tumors may be related to a mitogenic action of cholecystokinin and since there is no evidence that cholecystokinin has a mitogenic action in man, the clinical relevance of these findings is unknown. 

HP-β-CD has no antifertile effect, and is not mutagenic.
Treatment arm 1 targets a thyroid stimulating hormone (TSH) of 0.28 -2.49 milliunits/liter (mU/L) (the theoretical optimal range). The intervention is as follows: Levothyroxine (L-T4) doses will be adjusted in this arm to achieve this target TSH range. L-T4 is the intervention. L-T4 is given once per day, in the morning, while fasted. Dose ranges for the study are calculated based on each subject's TSH levels monitored during the study. Duration of the intervention is the duration of the study, after which subjects return to taking their usual L-T4 doses.
The invention discloses a method for establishing a rat Parkinson disease model by double-site combined injection of 6-OHDA and alpha-synuclein, which comprises the following steps: obtaining the site of the substantia nigra of the rat according to the brain localization map of the rat, wherein the coordinates of the two sites are as follows: 0.48cm behind bregma, 0.11cm to the right of midline of brain, and 0.8cm below the surface of dural shell; 0.48cm posterior to bregma, 0.19cm to the right of the midline of the brain, and 6-OHDA and AAV-alpha-synuclein were injected at two sites 0.75cm below the dural surface. And (3) carrying out rotation experiment detection on apomorphine hydrochloride injected subcutaneously at the head of the molded rat at the periphery after molding, wherein the rat rotates to the healthy side and the number of turns is more than 200r/30min, and the molding success is obtained. And if the number of turns is less than the specified value, the molding is considered to be failed. The invention selects the position with larger substantia nigra, and adopts two sites to inject the medicament with different depths, so that the dopamine neuron with the substantia nigra can be better injured. The success rate of molding can be improved, and the success rate of molding is over 90 percent. The success rate of other reported sites is generally lower than 80 percent at present, and the molding success rate is improved.